(Q34094831)

31 July 2017

1 reference

title

Prucalopride for constipation (English)

1 reference

31 July 2017

1 reference

1

Michael Camilleri

1 reference

31 July 2017

Annemie Deiteren

2

1 reference

ORCID Public Data File 2021

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

11

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

451-461

1 reference

Epidemiology of constipation in North America: a systematic review

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Cumulative incidence of chronic constipation: a population-based study 1988-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Chronic constipation: a survey of the patient perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

5-HT4 receptor agonists: similar but not the same

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Synergy between 5-HT4 receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

5-HT4 receptors located on cholinergic nerves in human colon circular muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Effect of enterokinetic prucalopride on intestinal motility in fast rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Prucalopride, a systemic enterokinetic, for the treatment of constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Intestinal macrophages display reduced permissiveness to human immunodeficiency virus 1 and decreased surface CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

A placebo-controlled trial of prucalopride for severe chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Psychometric validation of a constipation symptom assessment questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Treatment of chronic constipation with cisapride and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903567057

10.1517/14656560903567057

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference